open access

Vol 13, No 4 (2017)
Guidelines / Expert consensus
Published online: 2017-09-13
Get Citation

Cabozantinib for the treatment of renal cell carcinoma patients

Piotr Potemski, Cezary Szczylik, Piotr Tomczak, Piotr Wysocki, Jakub Żołnierek
DOI: 10.5603/OCP.2017.0019
·
Oncol Clin Pract 2017;13(4):147-155.

open access

Vol 13, No 4 (2017)
EXPERTS' OPINION
Published online: 2017-09-13

Abstract

Anti-angiogenesis is a key target of the first-line systemic therapy in renal cell carcinoma. Resistance to this therapy
ultimately occurs in almost every patient who requires subsequent treatment to manage disease progression.
Cabozantinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and additionally
blocking MET and AXL kinases, which are associated with tumour growth, proliferation, invasion, and resistance.
Cabozantinib has been shown to improve overall survival, progression-free survival, and objective response rate in
comparison to everolimus in patients with advanced renal cell carcinoma in the phase 3 METEOR study. It resulted
in the approval for use in the treatment of advanced renal cell carcinoma following prior vascular endothelial growth
factor (VEGF)-targeted therapy and contributed to a change of treatment guidelines, placing cabozantinib among
second-line therapy options. Herein we discuss the biological and clinical rationale behind cabozantinib use in
renal cell carcinoma therapy and its position in the rapidly developing renal cell carcinoma treatment landscape.
We outline current research and future directions for renal cell carcinoma therapy.

Abstract

Anti-angiogenesis is a key target of the first-line systemic therapy in renal cell carcinoma. Resistance to this therapy
ultimately occurs in almost every patient who requires subsequent treatment to manage disease progression.
Cabozantinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and additionally
blocking MET and AXL kinases, which are associated with tumour growth, proliferation, invasion, and resistance.
Cabozantinib has been shown to improve overall survival, progression-free survival, and objective response rate in
comparison to everolimus in patients with advanced renal cell carcinoma in the phase 3 METEOR study. It resulted
in the approval for use in the treatment of advanced renal cell carcinoma following prior vascular endothelial growth
factor (VEGF)-targeted therapy and contributed to a change of treatment guidelines, placing cabozantinib among
second-line therapy options. Herein we discuss the biological and clinical rationale behind cabozantinib use in
renal cell carcinoma therapy and its position in the rapidly developing renal cell carcinoma treatment landscape.
We outline current research and future directions for renal cell carcinoma therapy.

Get Citation

Keywords

anti-angiogenesis; cabozantinib; practice guidelines; renal cell carcinoma; tumour resistance

About this article
Title

Cabozantinib for the treatment of renal cell carcinoma patients

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 4 (2017)

Article type

Guidelines / Expert consensus

Pages

147-155

Published online

2017-09-13

DOI

10.5603/OCP.2017.0019

Bibliographic record

Oncol Clin Pract 2017;13(4):147-155.

Keywords

anti-angiogenesis
cabozantinib
practice guidelines
renal cell carcinoma
tumour resistance

Authors

Piotr Potemski
Cezary Szczylik
Piotr Tomczak
Piotr Wysocki
Jakub Żołnierek

References (50)
  1. GLOBOCAN 2012. Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. www. globocan.iarc.fr. (March 6th).
  2. Motzer R, Hutson T, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2007; 356(2): 115–124.
  3. Sternberg C, Davis I, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2010; 28(6): 1061–1068.
  4. Motzer R, Hutson T, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2013; 369(8): 722–731.
  5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med. 2007; 356(22): 2271–2281.
  6. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl_5): v58–v68.
  7. Powles T, Staehler M, Ljungberg B, et al. European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy. Eur Urol. 2016; 70(5): 705–706.
  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer version 1.2017. www.nccn.org. (February 6,2017).
  9. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7): 917–927.
  10. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1814–1823.
  11. Buti S, Leonetti A, Dallatomasina A, et al. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016; 11: 23–36.
  12. Choueiri T, Halabi S, Sanford B, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6): 591–597.
  13. Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000; 60(7): 1942–1948.
  14. Linehan W, Bratslavsky G, Pinto P, et al. Molecular Diagnosis and Therapy of Kidney Cancer. Annu Rev Med. 2010; 61(1): 329–343.
  15. Rini B, Campbell S, Escudier B. Renal cell carcinoma. Lancet. 2009; 373(9669): 1119–1132.
  16. Rankin E, Fuh K, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. PNAS. 2014; 111(37): 13373–13378.
  17. Rini B, Small E. Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma. J Clin Oncol. 2005; 23(5): 1028–1043.
  18. Lee J, Kim H, Jung J, et al. Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol. 2001; 77(1): 55–60.
  19. Na Xi, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003; 170(2 Pt 1): 588–592.
  20. Escudier B, Eisen T, Stadler W, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007; 356(2): 125–134.
  21. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605): 2103–2111.
  22. Rini B, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378(9807): 1931–1939.
  23. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372(9637): 449–456.
  24. Motzer R, Rini B, McDermott D, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015; 33(13): 1430–1437.
  25. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016; 35(21): 2687–2697.
  26. Gustafsson A, Matuszewska D, Johansson M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009; 15(14): 4742–4749.
  27. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 2009; 9(6): 785–793.
  28. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013; 24(2): 343–349.
  29. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors. Cancer Discov. 2012; 2(3): 270–287.
  30. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010; 70(24): 10090–10100.
  31. van der Mijn Jv, Broxterman H, Knol J, et al. Sunitinib activates Axl signaling in renal cell cancer. Int J Cancer. 2016; 138(12): 3002–3010.
  32. Qu L, Ding J, Chen C, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell. 2016; 29(5): 653–668.
  33. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol Cancer Ther. 2011; 10(12): 2298–2308.
  34. Fishman MN. Targeted therapy of kidney cancer: keeping the art around the algorithms. Cancer Control. 2013; 20(3): 222–232.
  35. Motzer R, Escudier B, McDermott D, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  36. European Medicines Agency. Cabometyx. Summary of product characteristics. www.ema.europa. (March 7th, 2017).
  37. Motzer R, Bacik J, Schwartz L, et al. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2004; 22(3): 454–463.
  38. Motzer R, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116(18): 4256–4265.
  39. Escudier B, Eisen T, Stadler W, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol. 2009; 27(20): 3312–3318.
  40. Cella D, Escudier B, Tannir N, et al. Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC). Ann Oncol. 2016; 27(suppl_6): 816P.
  41. Food and Drug Administration. Cabometyx. Prescribing Information. www.fda.com. (May 23rd, 2017).
  42. Food and Drug Administration. Lenvima. Prescribing Information. www.fda.com. (May 23rd, 2017).
  43. European Medicines Agency. Kisplyx. Summary of product characteristics. www.ema.europa. (March 7th, 2017).
  44. Motzer R, Hutson T, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15): 1473–1482.
  45. U.S. National Institutes of Health. NCT02231749 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214). www.clinicaltrial.gov. (March 8th, 2017).
  46. U.S. National Institutes of Health. NCT02853331 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426). www.clinicaltrial.gov. (March 8th, 2017).
  47. U.S. National Institutes of Health. NCT02420821 - A Study of Atezolizumab in Combination with Bevacizumab versus Sunitinib in Participants with Untreated Advanced Renal Cell Carcinoma. www.clinicaltrial.gov. (March 8th, 2017).
  48. U.S. National Institutes of Health. NCT02496208. Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors. U.S. National Institutes of Health. NCT02496208. Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors. www.clinicaltrial.gov..
  49. Driscoll J, Rixe O. Overall Survival: Still the Gold Standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009; 15(5): 401–405.
  50. Wiecek W, Karcher H. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma. PLoS One. 2016; 11(6): e0155389.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl